Asset profile
QR-333
Botanical
Evidence outlook · program status
Discontinued (2009), as a strategic decision by the sponsor
QR-333 was Quigley Pharma's topical natural-source formulation for diabetic peripheral neuropathy; its Phase 2b completed treatment in November 2008 and reported positive nerve-function findings in April 2009. ProPhase Labs (formerly The Quigley Corporation) states in its Form 10-K that after examining commercial viability in Fiscal 2009 and finding no third party willing to co-develop or license the compound it suspended Quigley Pharma's operations and stopped investing in it; status_date follows the Fiscal 2009 review the filing names. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.